For the past two years, compounding pharmacies offered a workaround for patients who couldn't afford brand-name GLP-1 medications: customized, lower-cost versions of semaglutide and tirzepatide mixed in-house. Hundreds of thousands of patients relied on them.
That's changing. The FDA is moving to permanently ban compounded semaglutide and tirzepatide, with a deadline of June 30, 2026 for most compounding pharmacies to stop producing them.
If you're currently using a compounding pharmacy for your GLP-1, this affects you directly. Here's what you need to know.
Why the FDA Is Banning Compounded GLP-1s
The FDA can authorize compounding pharmacies to produce drugs that are in shortage. In 2022 and 2023, both semaglutide and tirzepatide were placed on the FDA shortage list, opening the door for compounders to legally produce them at scale.
The FDA has since determined the shortage is over — both drugs are now widely available through their brand-name manufacturers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide). With the shortage resolved, the legal basis for compounding these specific drugs no longer exists.
Beyond the legal issue, the FDA cited 455 adverse event reports linked to compounded semaglutide, including dangerous dosing errors. Some compounded formulations contained 5 to 20 times the intended dose, leading to serious hospitalizations. The agency also raised concerns about quality control at some compounding facilities.
What "Compounded" Means (and Why It Was Cheaper)
Compounding pharmacies are licensed to produce customized medications — adjusting doses, removing allergens, or combining drugs — for patients who can't use commercially available versions. They operate under state licensing and some federal oversight, but they don't go through the same rigorous FDA approval process that brand-name manufacturers do.
Compounded semaglutide and tirzepatide were typically much cheaper: $150–$300/month versus $500–$935/month for branded versions. The tradeoff was less quality oversight and the uncertainty of sourcing.
What Happens After June 30
After the deadline, most compounding pharmacies must stop producing semaglutide and tirzepatide. Patients who were getting GLP-1 medications through compounders will need to transition to:
- Brand-name GLP-1s through traditional or specialty pharmacies
- Manufacturer patient assistance programs (if income-eligible)
- Manufacturer self-pay rates (now $349/month for Ozempic/Wegovy, $499/month for Zepbound)
Some "503B outsourcing facilities" — higher-regulated compounders that supply healthcare providers rather than patients directly — may have a longer compliance window. If you get your medication through a medical clinic rather than a retail compounding pharmacy, ask your provider whether their supplier is a 503A or 503B facility.
What You Should Do Now
If you're currently using a compounding pharmacy:
-
Talk to your prescriber immediately. They need to transition you to a branded prescription before your compounded supply runs out.
-
Check your insurance. If you're newly coming to a brand-name GLP-1 prescription, your insurance may cover it — especially if your diagnosis is type 2 diabetes.
-
Check PAP eligibility. If you were using a compounding pharmacy specifically because you couldn't afford brand-name pricing, you may qualify for Novo Nordisk's NovoCare PAP or Lilly Cares Foundation — providing the medication free if you meet income requirements.
-
Don't panic-stockpile. Compounders are required to stop producing, not to destroy existing stock. Supplies will wind down over time, not overnight.
A Note on Safety
If you've been using compounded semaglutide without issues, it doesn't mean your compounder was cutting corners. Many operated responsibly. But the lack of uniform oversight meant there was no reliable way for patients to tell the difference. The transition to regulated, brand-name medications is, from a safety standpoint, a positive outcome — particularly if cost barriers can be addressed through assistance programs.
ClariMeds Can Help With the Transition
If you're coming off compounded GLP-1s and need help accessing brand-name Ozempic, Wegovy, Mounjaro, or Zepbound affordably, ClariMeds checks your eligibility for every applicable program and handles the application process.
Check your options — takes about 5 minutes
This article is for informational purposes only. If you are currently using a compounded medication, consult your prescribing provider before making any changes.